Home | GSK US
January 07 2025 GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma December 16 2024 Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
Products - GSK US
We deliver over 1.5 million doses of our vaccines every day; and 4 out of 10 infants born each year receive at least one GSK vaccine. Our vaccines portfolio targets infectious diseases at every stage of life, helping to protect people from RSV, meningitis, shingles, flu, polio and many more.
At a glance | GSK US
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US; Our largest US-based operation, the Upper Providence R&D hub features 8 smart labs and more than 3,000 GSK people discovering and developing new medicines which will change lives.
Careers - GSK US
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Company | GSK US
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US
Press releases | GSK US
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation based on promising early data in this rare bone cancer.
Search jobs | GSK US
Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG. GSK websites; GSK Global website; Locations selector; Global Behind the science; GSKPro for HCPs; ViiV Healthcare;
US FDA approves GSK’s AREXVY, the world’s first respiratory …
2023年5月3日 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
Purpose, strategy and culture | GSK US
Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. GSK is a company where outstanding people can thrive. We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to …
Contact us - GSK
Contact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for certain GSK products.